Trial site
Ehime
Ehime, 790-0024, JapanNot linked to an institution yet
- 11running trials
- 4closed trials
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 312 trials
- Phase 22 trials
- Phase 41 trial
- Status
- Active, not recruiting6 trials
- Recruiting5 trials
- Completed4 trials
Running trials
Recruiting
Efficacy and Safety of Depemokimab Monotherapy Without Concomitant Use of Intranasal Corticosteroids (INCS) in Japanese Participants With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
NCT07701967· Phase 4· GlaxoSmithKline· Source
Contact: Nobumitsu Honda (principal investigator)
Recruiting
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
NCT07227311· Phase 2· GlaxoSmithKline· Source
Contact: Tomoaki Fujisaki (principal investigator)
Recruiting
A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)
NCT06679101· Phase 3· GlaxoSmithKline· Source
Contact: Koichi Nakase (principal investigator)
Recruiting
A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease
NCT06613698· Phase 2· GlaxoSmithKline· Source
Contact: Hideko Ohama (principal investigator)
Active, not recruiting
A Study of Belrestotug Plus Dostarlimab Compared With Placebo Plus Pembrolizumab in Previously Untreated Participants With Programmed Death Ligand 1 (PD-L1) High Non-small-cell Lung Cancer (NSCLC)
NCT06472076· Phase 3· GlaxoSmithKline· Source
Recruiting
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
NCT06256588· Phase 3· GlaxoSmithKline· Source
Contact: Nobuya Monden (principal investigator)
Active, not recruiting
Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease
NCT04915755· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma
NCT04484623· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Linerixibat Long-term Safety, and Tolerability Study
NCT04167358· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
NCT04246047· Phase 3· GlaxoSmithKline· Source
Active, not recruiting
Study of Single Agent Belantamab Mafodotin Versus Pomalidomide Plus Low-dose Dexamethasone (Pom/Dex) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)
NCT04162210· Phase 3· GlaxoSmithKline· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error